Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:34 PM
Ignite Modification Date:
2025-12-24 @ 2:34 PM
NCT ID:
NCT02655159
Eligibility Criteria:
Inclusion Criteria:
* Women ≥18 years of age.
* Confirmed diagnosis of MBC (stage IV).
* Breast adenocarcinoma confirmed histologically.
* HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.
* Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.
* Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).
Exclusion Criteria:
* Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.
* Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.
* Patients who have taken part in any clinical trial (interventional) during the study period.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT02655159
Study Brief:
Protocol Section:
NCT02655159